(Total Views: 620)
Posted On: 09/12/2020 8:57:05 PM
Post# of 148899
Thanks, CT, there's one there I haven't seen before.
These are just three studies, all small populations of 100-200 people, and maybe all heterozygous CCR5delta32.
There are at least as many other similarly sized studies in other geographic regions that suggest CCR5delta32 is protective.
When I checked I read six or seven papers. They were all the same. 200 patients, heterozygous mostly, in some particular small geographic region. i saw about 2:1 in favor of protective over hazardous.
There is just no clear signal from these studies on the impact of heterozygous ccr5delta32.
The homozygous CCR5delta32 is way more important anyways cuz heterozygous just changes the quantity of CCR5 receptors by 50% if all other factors are equal, which they are almost certainly not.
I found one CCR5 knockout study in mice which was mitigating but not curative for EAE. Pourhassan claims leronlimab rescued three EAE mice. Probably doesnt mean anything but it might be a starting point.
These are just three studies, all small populations of 100-200 people, and maybe all heterozygous CCR5delta32.
There are at least as many other similarly sized studies in other geographic regions that suggest CCR5delta32 is protective.
When I checked I read six or seven papers. They were all the same. 200 patients, heterozygous mostly, in some particular small geographic region. i saw about 2:1 in favor of protective over hazardous.
There is just no clear signal from these studies on the impact of heterozygous ccr5delta32.
The homozygous CCR5delta32 is way more important anyways cuz heterozygous just changes the quantity of CCR5 receptors by 50% if all other factors are equal, which they are almost certainly not.
I found one CCR5 knockout study in mice which was mitigating but not curative for EAE. Pourhassan claims leronlimab rescued three EAE mice. Probably doesnt mean anything but it might be a starting point.
(0)
(0)Scroll down for more posts ▼
